Current Headlines

  1. Breaking The Safety Barrier: Insilico Medicine Nominates ISM1354, The Next-Generation Small Molecule GIPR Antagonist 9/30/2026

    As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth.

  2. FDA Accepts New Drug Application For CeleCor's Investigational Heart-Attack Drug 9/30/2026

    The U.S. Food and Drug Administration has accepted CeleCor Therapeutics' New Drug Application (NDA) for zalunfiban (DisaggproTM) and assigned a target action date of June 18, 2027 under the Prescription Drug User Fee Act (PDUFA).

  3. Tremont AI Emerges From Stealth To Bring Multimodal AI To Preclinical Drug Safety 9/29/2026

    Tremont AI, a biomedical AI company focused on preclinical drug safety, today emerged from stealth. The company is developing multimodal foundation models and AI agents to help scientists analyze and interpret evidence across preclinical safety studies.

  4. Corbus Pharmaceuticals Announces First Patient Dosed In TEMPO-1 Registrational Study Of CRB-701 In Patients With 2L+ Oropharyngeal Cancer 9/29/2026

    Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate (ADC), in second-line and beyond (2L+) oropharyngeal squamous cell carcinoma (OPSCC).

  5. HUTCHMED Announces Submission Of US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated Lung Cancer 9/29/2026

    HUTCHMED (China) Limited (“HUTCHMED”) today announces that AstraZeneca has submitted a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.

  6. BRC Therapeutics Joins FDA And EMA Regulators At Workshop Advancing The Future Of Botanical Drug Development 9/28/2026

    BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, today announced its participation in the Regulatory Perspectives on Herbal Medicinal/Botanical Drug Product Development workshop, a joint session convened by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in Amsterdam, the Netherlands.

  7. Lupin Receives Tentative Approval From U.S. FDA For Novel Apixaban Oral Suspension 9/28/2026

    Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.

  8. Bruker Advances Functional Proteomics With Novel timsUltra AIP And timsOmni Workflows For Drug Discovery & Development And Disease Biology Research 9/28/2026

    At the Human Proteome Organization World Congress 2026, Bruker Corporation today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis.

  9. Mission Bio Showcases Tapestri Across Drug Discovery And Clinical Development At World CDx Summit 9/28/2026

    Mission Bio, the single-cell multiomics leader, today announced that Merck & Co. and Incyte will each present new data generated using Mission Bio’s Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit (World CDx), alongside a third presentation from Mission Bio featuring new clinical data in acute myeloid leukemia.

  10. Future Fields Closes Oversubscribed $8M Series A to Turn Flies Into Bioreactors That Address Undruggable Diseases 9/26/2026